Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells
Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.
The major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.
|Pregnant, Healthy Females Healthy Male Newborns|
|Study Design:||Observational Model: Case-Control
Time Perspective: Prospective
|Official Title:||Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells|
|Study Start Date:||November 2008|
|Estimated Study Completion Date:||December 2020|
|Estimated Primary Completion Date:||December 2020 (Final data collection date for primary outcome measure)|
Pre-existing Fibroblast MCB
Pre-existing fibroblast donors for hESC derivation project
The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.
The clinical grade donated feeders used in this project were developed under GMP conditions using animal-free reagents. For potential future clinical applications, the iPS cells will be developed under GMP conditions, using reagents and methods that will be acceptable for clinical applications.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00801372
|Contact: Benjamin E Reubinoff, PhD MDemail@example.com|
|Contact: Shelly E. Tannenbaum, MSQAfirstname.lastname@example.org|
|Hadassah Ein Kerem||Recruiting|
|Jerusalem, Israel, 9112100|
|Contact: Benjamin E Reubinoff, Professor 972-2-6776424/5 email@example.com|
|Contact: Shelly E Tannenbaum, MSQA 972-2-6775700 firstname.lastname@example.org|